
Opinion|Videos|May 28, 2024
CSF Testing and Blood-based Biomarkers in Alzheimer’s Disease
Panelists review the use of CSF and blood-based biomarkers in Alzheimer's disease, discussing the role of tau as a marker of neuronal injury and its utility in staging the progression of Alzheimer's disease.
Advertisement
Episodes in this series

Video content above is prompted by the following questions:
- Describe the use of CSF and blood-based biomarkers in AD.
- Which biomarkers/histopathological features are associated with different stages of Alzheimer’s disease?
- What are you using in your practice?
- What are the unmet needs?
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
How Multiple Sclerosis Affects Men
2
ECTRIMS Congress 2025: Top Expert Interviews and Key Takeaways
3
NeurologyLive® Brain Games: October 12, 2025
4
The Future of Disease-Modifying Therapy in Epilepsy
5